VolitionRX Ltd (VNRX): Next-Year EPS Estimate 64.52%
As of 2026-09-01, VolitionRX Ltd (VNRX) has a next-year EPS growth estimate of 64.52%. Featured in our EPS revision report on 2026-05-25.
On 2026-08-25, analyst consensus for VNRX's next-year EPS growth shifted from 60.32% to 64.52% — a positive change of 4.20 percentage points. The revised estimate has been sustained across 8 subsequent trading sessions. Current-year growth is projected at 53.03%.
What's Driving This
The primary driver is a sharp upward revision to VNRX’s next-year EPS growth estimate, raised from 47.14% to 60.32% on 2026-08-18 and now at 64.52%. This upgrade aligns with recent catalysts, including the Q1 2026 earnings call highlighting a revenue surge and the announced breakthrough finger-prick detection of nucleosomes for sepsis testing. The estimate has continued rising over two trading sessions, reflecting sustained positive momentum in analyst expectations.
Generated 2026-09-01 from news as of 2026-09-01
Current Snapshot
- Sector
- Healthcare
- Industry
- Medical Devices
- EPS growth next year
- 64.52%
- EPS growth this year
- 53.03%
- EPS next quarter (est)
- -$0.38
- Last price
- $0.43
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-09-01 | 64.52% | 53.03% | -$0.38 | $0.43 |
| 2026-08-31 | 64.52% | 53.03% | -$0.38 | $0.43 |
| 2026-08-30 | 64.52% | 53.03% | -$0.38 | $0.45 |
| 2026-08-29 | 64.52% | 53.03% | -$0.38 | $0.45 |
| 2026-08-28 | 64.52% | 53.03% | -$0.38 | $0.45 |
| 2026-08-27 | 64.52% | 53.03% | -$0.38 | $0.50 |
| 2026-08-26 | 64.52% | 53.03% | -$0.38 | $0.34 |
| 2026-08-25 | 64.52% | 53.03% | -$0.38 | $0.38 |
| 2026-08-24 | 60.32% | 54.32% | -$0.38 | $0.39 |
| 2026-08-23 | 60.32% | 54.32% | -$0.38 | $0.42 |
| 2026-08-21 | 60.32% | 54.32% | -$0.38 | $0.42 |
| 2026-08-20 | 60.32% | 54.32% | -$0.38 | $0.44 |
| 2026-08-19 | 60.32% | 54.32% | -$0.38 | $0.49 |
| 2026-08-18 | 60.32% | 54.32% | -$0.38 | $0.47 |
| 2026-08-17 | 47.14% | 54.32% | -$0.36 | $0.50 |
| 2026-08-16 | 47.46% | 50.80% | -$0.43 | $0.54 |
| 2026-08-14 | 47.46% | 50.80% | -$0.43 | $0.54 |
| 2026-08-13 | 47.46% | 50.80% | -$0.57 | $0.63 |
| 2026-08-12 | 47.46% | 50.80% | -$0.57 | $0.67 |
| 2026-08-11 | 47.46% | 50.80% | -$0.57 | $0.72 |
| 2026-08-10 | 47.46% | 50.80% | -$0.57 | $0.77 |
| 2026-08-09 | 47.46% | 50.80% | -$0.57 | $0.78 |
| 2026-08-07 | 47.46% | 50.80% | -$0.57 | $0.78 |
| 2026-08-06 | 49.13% | 49.18% | -$0.61 | $0.77 |
| 2026-08-05 | 49.13% | 49.18% | -$0.61 | $0.80 |
| 2026-08-04 | 49.13% | 49.18% | -$0.61 | $0.79 |
| 2026-08-03 | 49.13% | 49.18% | -$0.61 | $0.80 |
| 2026-08-02 | 49.13% | 49.18% | -$0.61 | $0.72 |
| 2026-07-31 | 49.13% | 49.18% | -$0.61 | $0.72 |
| 2026-07-30 | 49.13% | 49.18% | -$0.61 | $0.80 |
Reports Featuring VNRX
Recent News
- VolitionRX Ltd (VNRX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...GuruFocus.com
- VolitionRX Ltd (VNRX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...GuruFocus.com
- Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis TestingPR Newswire
- VolitionRX: Q4 Earnings SnapshotAssociated Press
- VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business UpdatePR Newswire
- VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business UpdatePR Newswire
- VolitionRX Ltd (VNRX) Q4 2025: Everything You Need to Know Ahead of EarningsGuruFocus.com
- VolitionRX Ltd (VNRX) Q4 2025: Everything You Need to Know Ahead of EarningsGuruFocus.com
- VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in BelgiumPR Newswire
- VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in BelgiumPR Newswire
Screen Performance
Aggregate stats across all 2024 tickers our top-EPS-revision screen has flagged over the past 153 days.
- Median return since detection
- +1.8%
- % of tickers in the green
- 54%
- Median return on winners
- +20.3%
- Large revisions captured
- 1641
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is VolitionRX Ltd's next-year EPS growth estimate?▾
As of 2026-09-01, VolitionRX Ltd (VNRX) has a next-year EPS growth estimate of 64.52%, based on analyst consensus.
When was the latest EPS estimate revision for VNRX?▾
The most recent revision occurred on 2026-08-25, when analysts adjusted the next-year EPS growth estimate from 60.32% to 64.52%.
What sector and industry does VolitionRX Ltd belong to?▾
VolitionRX Ltd operates in the Healthcare sector, specifically the Medical Devices industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. VNRX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. VolitionRX Ltd (VNRX) appears here because it was detected by our daily top-EPS-revision-performer screen.